|04 July 2018|
|Big Healthcare Plays a Key Market Highlight of 1H18|
Coupled with gains in the US Dollar, ongoing trade disputes shaped the biggest challenge to the global stock market in the first half of 2018. Much of the volatility associated with the very open trade and tariff dialogues was absorbed by equities – while commodities, interest rates and currencies were more influenced by economic drivers.
Big Global Healthcare Stocks a Highlight of 1H18
One defensive segment of the stock market that performed comparatively well in the first of 2018 were the traditional healthcare providers in the both United States and Asia Pacific. Half of the 10 largest capitalised healthcare equipment and service providers in the United States achieved double digit gains, as did six of the relevant 10 largest stocks in Asia Pacific.
Regional Sector Dynamics
Within the stock market, healthcare providers are typically known to be a defensive segment. However, the landscape of burgeoning demand and comparatively lagged supply of equipment and services in South East Asia provides a significant growth connexion.
Investors are well aware of the region’s large growing rural and urban populations, rising affluence and increased incidence of treatable diseases. At the same time the number of physicians, nurses and levels of government expenditure maintained by our South East Asia neighbours is well below the World Bank’s global average. As recently highlighted by healthcare private equity fund, Quadria Capital, many of the economies in Southeast Asia have a relatively underdeveloped healthcare system.
Expanding the quality of clinical and specialist patient care, achieving more operational scale and the application of frontline technology provide potential growth drivers for the Sector. Frost & Sullivan estimate that the Asia-Pacific healthcare industry represents one of the fastest growing regions in the world in 2018, fuelled by increasing adoption of technology, innovative healthcare access programs and delivery of care outside traditional hospital settings.
As discussed here the majority of the biggest healthcare stocks have also pursued growth strategies in recent years. It has been 10 years since ParkwayLife REIT extended its regional reach outside of Singapore with its maiden entry into Japan. From the 10 year period spanning its IPO to the end of 2017, ParkwayLife REIT grew its number of properties from three to 49, portfolio value from S$775 million to S$1.73 billion, gearing ratio from 4.3% to 36.4% and market capitalisation from S$770 million to S$1.81 billion.
Singapore’s 10 Largest Healthcare Index Stocks Mixed, Averaged 6% Return in 2018 YTD
Singapore’s SGX All Healthcare Index has gained 6.0% in the 2018 year through to 3 July. This has brought its average annualised total return over the past five years to 7.3%, which compared to 4.1% for the Straits Times Index (“STI”). The Healthcare Sector was also the strongest of the Sectors in Singapore in June 2018. While the Sector saw net institutional outflow of S$0.4 million in June, it was one of just two Sectors that had booked inflow for each of the three preceding months of March through May.
The 10 largest constituents of the SGX All Healthcare Index averaged a similar total return to the SGX All Healthcare Index in the year thus far, with individual performances tabled below. To see more details on each stock in SGX StockFacts click on the stock name.
Source: Bloomberg & SGX StockFacts (data as of 03 July 2018). *Note: Tianjin Zhong Xin Pharm are traded in USD however SGD equivalents are shown in table for performances.
Note that increased competition through lower-cost treatments and new start-ups, in addition to rising labour and capital costs are challenges for healthcare providers. For those healthcare service and equipment business that are expanding across the not just the region, geopolitical and exchange rate volatility also present potential challenges.
10 Biggest Index Weights Averaged 14% Annualised Returns over Past Five Years.
Corresponding with the general observation that a number of healthcare stocks have transposed their identity as traditional defensive plays, all 10 of the stocks tabled above have generated gains over the past five years. The 10 stocks also maintain an above average price-to-earnings ratio of 30.7x.
Reflecting diversity of equipment and services in addition to other healthcare segments such as pharmaceuticals there has also been a high degree of variation in the past five year gains. Average annualised total returns for the past five years ranged from 0.4% for Raffles Medical Group to 38.9% for Health Management International.
Of these 10 stocks, just the one stock, Top Glove Corporation Bhd, listed within the five year period. If included, its return from the listing date would bring the average annualised return of the 10 stocks up to 19.0%. On average the nine of the 10 stocks that have been listed of the duration generated average annualised returns of 14.3%.
The next five largest weights of the SGX All Healthcare Index include three stocks that have been listed for the duration that averaged 22.9% annualised gains over the past five years. If including the returns of TalkMed Group and Clearbridge Health which listed in the interim, the average annualised return of these next five largest weights of the Index would have been 27.4%.
|My Gateway & SGX StockFacts|
SGX’s investor education portal with market, product and investment information and events. Sign up now at sgx.com/mygateway to receive our investment updates and economic calendar.
Whether you are seeking new or established companies to invest in, SGX StockFacts can provide you with the information you need to identify and understand the stocks that best fit your investment strategy. Visit now at sgx.com/stockfacts
This document is not intended for distribution to, or for use by or to be acted on by any person or entity located in any jurisdiction where such distribution, use or action would be contrary to applicable laws or regulations or would subject Singapore Exchange Limited (“SGX”) to any registration or licensing requirement. This document is not an offer or solicitation to buy or sell, nor financial advice or recommendation for any investment product. This document is for general circulation only. It does not address the specific investment objectives, financial situation or particular needs of any person. Advice should be sought from a financial adviser regarding the suitability of any investment product before investing or adopting any investment strategies. Use of and/or reliance on this document is entirely at the reader’s own risk. Further information on this investment product may be obtained from www.sgx.com. Investment products are subject to significant investment risks, including the possible loss of the principal amount invested. Past performance of investment products is not indicative of their future performance. Examples provided are for illustrative purposes only. While each of SGX and its affiliates (collectively, the “SGX Group Companies”) have taken reasonable care to ensure the accuracy and completeness of the information provided, each of the SGX Group Companies disclaims any and all guarantees, representations and warranties, expressed or implied, in relation to this document and shall not be responsible or liable (whether under contract, tort (including negligence) or otherwise) for any loss or damage of any kind (whether direct, indirect or consequential losses or other economic loss of any kind, including without limitation loss of profit, loss of reputation and loss of opportunity) suffered or incurred by any person due to any omission, error, inaccuracy, incompleteness, or otherwise, any reliance on such information, or arising from and/or in connection with this document. The information in this document may have been obtained via third party sources and which have not been independently verified by any SGX Group Company. No SGX Group Company endorses or shall be liable for the content of information provided by third parties. The SGX Group Companies may deal in investment products in the usual course of their business, and may be on the opposite side of any trades. SGX is an exempt financial adviser under the Financial Advisers Act (Cap. 110) of Singapore. The information in this document is subject to change without notice. This document shall not be reproduced, republished, uploaded, linked, posted, transmitted, adapted, copied, translated, modified, edited or otherwise displayed or distributed in any manner without SGX’s prior written consent.
Nikkei owns the copyright and any other intellectual property rights in the Nikkei Stock Average itself, and the method for calculating the Nikkei Stock Average and the like. All ownership of trademarks and any other intellectual property rights with respect to marks representing "Nikkei Inc.," "Nikkei," and "Nikkei Stock Average" belongs to Nikkei. Nikkei is not obliged to continuously publish the Nikkei Stock Average, nor is it liable for any error or delay in, or discontinuation of the publication thereof. Nikkei owns the right to change the content of the Nikkei Stock Average, such as the calculation method thereof, and the right to suspend the publication thereof. Nikkei does not give any warranty, nor is it responsible for any and all financial instruments and the like, which are based on, or otherwise refer to, the Nikkei Stock Average.
All rights in the FTSE China A50 Index (the “Index”) vest in FTSE International Limited (“FTSE”). “FTSE®” is a trademark of the London Stock Exchange Group companies and is used by FTSE under license.
The SGX FTSE China A50 Index Futures (the "Product") has been developed solely by Singapore Exchange Derivatives Trading Limited. The Index is calculated by FTSE or its agent. FTSE and its licensors are not connected to and do not sponsor, advise, recommend, endorse or promote the Product and do not accept any liability whatsoever to any person arising out of (a) the use of, reliance on or any error in the Index or (b) investment in or operation of the Product. FTSE makes no claim, prediction, warranty or representation either as to the results to be obtained from the Product or the suitability of the Index for the purpose to which it is being put by Singapore Exchange Derivatives Trading Limited.
Futures or options contract on any MSCI Index are not sponsored, guaranteed, endorsed, sold or promoted by MSCI, any affiliate of MSCI or any other party involved in, or related to, making or compiling any indexes (but expressly including the exchange) MSCI bears no liability of any kind with respect to such contracts